KOSDAQBiotech & Pharma445680

Curiox Biosystems

₩57,100▼ 3.55%2026-10-02 close

Market Cap

₩1T

Turnover

₩3.1B

Volume

50,000 shares

Shares out.

17.2M

PER

—

PBR

20.6×

EPS

-₩726

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Loss-Making Firm Bets on a Software Pivot

Curiox Biosystems is pushing a business-model shift from hardware-centric sales toward recurring-revenue software 'Pluto Code,' even as operating losses and cash burn continue.

1
2025 revenue rebounded to KRW 5.1515 billion year over year, but the operating loss remained at KRW 12.3144 billion.
2
In April 2026 the company signed its first master license agreement for Pluto Code software with an undisclosed global top-10 pharmaceutical company.
3
The 2026 Q2 operating loss (-KRW 4.4572 billion) widened from Q1 (-KRW 3.2519 billion), showing volatility in the pace of margin improvement.
4
Operating cash flow posted net outflows of KRW 8.2–11.1 billion every year from 2022 to 2025, keeping the company reliant on external funding.
5
The 2025 Q2 net loss attributable to owners (-KRW 18.2618 billion) far exceeded that quarter's operating loss (-KRW 3.9575 billion), pointing to significant non-operating earnings volatility.

Business structure

Curiox Biosystems was founded in Singapore in 2008 and established a Korean subsidiary in 2018; it now operates headquarters and manufacturing in Korea, sales subsidiaries in Boston and Shanghai, and an R&D/manufacturing entity in Singapore.

Since its founding the company has positioned itself as a life-science technology firm automating and standardizing sample preparation for cell analysis around its proprietary C-FREE technology.

Its core value proposition replaces centrifugation with software-controlled pipetting-based washing to reduce cell damage and improve data reproducibility.

Its flagship products are the hardware Pluto Workstation series (LT, MT, HT) and Pluto Code, a software solution that can be installed on liquid-handling equipment customers already own.

Hardware manufacturing relies on an OEM arrangement with global lab equipment maker Revvity, with monthly production capacity at its Hong Kong facility reported at around 700 units.

Starting in 2026, Pluto Code is planned to extend compatibility beyond the company's own hardware to competitor workstations such as Beckman Coulter and Hamilton, making hardware rivals simultaneously a distribution channel for its software.

Customers span global pharmaceutical, biotech, and research institutions; according to an earlier media report, Laminar Wash-based products had been supplied to 18 of the top 20 global biopharma companies, including Pfizer, AstraZeneca, and GSK.

A March 2026 Samsung Securities report noted that global CRO IQVIA and AstraZeneca were already using Pluto Wash features in research or evaluating them as next-generation technology.

Earnings trend

Quarterly revenue · Operating profit

₩1B-₩4B25Q2₩1.4B-₩2.7B25Q3₩1.8B-₩2.7B25Q4₩1.3B-₩3.3B26Q1₩1.2B-₩4.5B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩7.2B-₩11.4B2022₩6.8B-₩10.6B2023₩4.6B-₩13.4B2024₩5.2B-₩12.3B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩1B	-₩4B	−397.5%
2025Q3	₩1.4B	-₩2.7B	−193.6%
2025Q4	₩1.8B	-₩2.7B	−143.4%
2026Q1	₩1.3B	-₩3.3B	−245.5%
2026Q2	₩1.2B	-₩4.5B	−379.1%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩7.2B	-₩11.4B	-₩11.5B	−157.8%	−26.2%	10.9%
2023	₩6.8B	-₩10.6B	-₩10B	−155.5%	−19.0%	9.3%
2024	₩4.6B	-₩13.4B	-₩8.1B	−291.6%	−16.6%	45.1%
2025	₩5.2B	-₩12.3B	-₩27.2B	−239.0%	−51.5%	47.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

Annual revenue fell for two consecutive years from KRW 7.236978 billion in 2022 to KRW 6.787911 billion in 2023 and KRW 4.587637 billion in 2024, before rebounding to KRW 5.151548 billion in 2025.

The operating loss widened from KRW 11.4210 billion in 2022 and KRW 10.5571 billion in 2023 to KRW 13.3778 billion in 2024, then narrowed slightly to KRW 12.3144 billion in 2025.

Net loss attributable to owners narrowed from KRW 11.4947 billion in 2022 to KRW 10.0404 billion in 2023 and KRW 8.0890 billion in 2024, but then widened sharply to KRW 27.1767 billion in 2025.

On a quarterly basis, the 2025 Q2 net loss attributable to owners reached KRW 18.2618 billion, far exceeding that quarter's operating loss of KRW 3.9575 billion, indicating a substantial swing in non-operating items.

The net loss then gradually narrowed over 2025 Q3 (-KRW 3.0295 billion), Q4 (-KRW 2.2680 billion) and 2026 Q1 (-KRW 2.6411 billion), before widening again to -KRW 4.8410 billion in 2026 Q2.

The operating loss also grew from KRW 3.2519 billion in 2026 Q1 to KRW 4.4572 billion in Q2, even as revenue declined from KRW 1.3249 billion to KRW 1.1756 billion over the same period, reflecting a combination of lower sales and sustained cost pressure.

Operating cash flow posted net outflows every year—KRW 9.8880 billion in 2022, KRW 8.1642 billion in 2023, KRW 9.6982 billion in 2024 and KRW 11.1092 billion in 2025—showing that operating cash generation alone has not covered the company's cost base.

Total equity actually rose from KRW 48.6375 billion in 2024 to KRW 52.8096 billion in 2025 despite the large net loss, suggesting external capital raising occurred alongside the losses.

Total liabilities likewise jumped from KRW 4.9145 billion in 2023 to KRW 21.9231 billion in 2024 and further to KRW 25.2179 billion in 2025, consistent with the use of financing instruments such as convertible bonds.

Industry analysis

The lab automation and life-science tools segment in which Curiox operates is forecast to grow at roughly an 8% compound annual rate according to a Samsung Securities analysis, with expanding cell and gene therapy (CGT) development and AI/machine-learning-driven drug discovery pushing demand for automation and standardization.

The company has estimated the addressable market for manual, centrifugation-based cell analysis at roughly KRW 19 trillion and has set a long-term target of capturing between 30% and 50% of that market.

Company representatives have acknowledged, however, that the next one to two years represent an early demand-formation phase, with meaningful share gains expected only after standardization and validation are completed from the third year onward, implying market penetration will take time.

The competitive landscape includes both traditional centrifugation-based workstation makers and liquid-handling equipment companies such as Beckman Coulter and Hamilton; Pluto Code is designed to be compatible with these rivals' equipment, creating a structure of simultaneous competition and cooperation.

In August 2025, global CRO Charles River formalized a collaboration in which it uses Curiox's technology and equipment as part of its automation strategy, highlighting the company's positioning in the preclinical segment.

In terms of scale, the company's revenue has remained around KRW 5 billion for several years since listing, which some observers note reflects the limits of growth under a hardware-sales-centric model alone.

Outlook

In an IR letter updated in January 2026, Curiox identified partnership agreements with global equipment makers, comprehensive supply agreements with global pharma and biotech companies, and co-marketing and comprehensive supply agreements with global CRO/CDMO firms as its key growth drivers for the year.

The company followed through on April 22, 2026, officially announcing it had signed its first comprehensive software license agreement for Pluto Code deployment with an undisclosed large global pharmaceutical company, under which that customer can install Pluto Code on workstations across its global organization under a single contract.

In June 2026 the company released new software, including a 'Workflow Wizard,' allowing researchers to operate equipment using their existing experimental protocols without programming knowledge, continuing its strategy of lowering adoption barriers.

In August 2026 it disclosed, through its U.S. subsidiary, a KRW 510 million order for multiple 'Pluto HT' units from a leading global pharmaceutical company in the cell and gene therapy field, noting that two multi-unit equipment contracts were completed in that quarter alone.

Management has stated it expects software's share of the business to overtake hardware within three years.

However, in a September 2026 interview, CEO Nam-yong Kim noted that because the comprehensive-contract model is new, decision-making by big pharma executives has been slower than expected, and he said the company planned to officially announce an AI-based data analytics collaboration with a large global company as early as late August to September 2026—whether that announcement has actually occurred needs to be confirmed through subsequent disclosures.

Valuation

PER

—

PBR

20.6×

ROE

-33.5%

EPS

-₩726

BPS

₩2,854

Dividend per share

₩0

The current share price appears to trade at a notable premium to book net assets, a level consistent with the upper end of its historical trading range. Because operating losses and volatile non-operating items persist, earnings-based valuation metrics remain difficult to calculate in any meaningful way.

With no dividend payment history, a yield-based comparison is not applicable.

Over the multi-year trend, revenue has shifted from decline to rebound, but the loss-making pattern itself continues, making the pace of any future profitability recovery and the expansion of software's revenue share the key variables shaping how the valuation is assessed going forward.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Recurring-Revenue Model from the Software Pivot

The Pluto Code comprehensive license agreement signed in April 2026 is structured so that after a single initial contracting process, subsequent purchases are handled through simplified ordering.

This supports a shift away from the prior hardware-sales-centric model toward a platform business capable of generating recurring revenue. Management has said it expects software's share of the business to overtake hardware within three years.

Because software carries essentially no manufacturing cost burden, a shift in revenue mix has the potential to translate into improved profitability.

Expanding Global Reference Base

According to an earlier media report, the company had supplied products to 18 of the top 20 global biopharma companies, including Pfizer, AstraZeneca, and GSK, and a 2026 Samsung Securities report noted that IQVIA and AstraZeneca were using Pluto Wash features in research or evaluating them as next-generation technology.

In August 2025, global CRO Charles River formalized its use of Curiox technology as part of its own automation strategy. In August 2026, the company disclosed a multi-unit equipment order from a leading global pharmaceutical company in the cell and gene therapy field. This accumulating reference base can serve as supporting evidence when courting new customers.

Revenue Rebound Alongside External Funding

Revenue rebounded to KRW 5.151548 billion in 2025 from the prior year, ending a two-year decline. Despite a large net loss over the same period, total equity rose from KRW 48.6375 billion to KRW 52.8096 billion, suggesting external capital raising occurred in parallel, securing liquidity needed to sustain operations. This can provide a base for continued investment in R&D and sales expansion.

Bear factors

Persistent Large Operating Losses and Cash Burn

The operating loss ranged from the high KRW 10 billion range to the mid KRW 13 billion range every year from 2022 to 2025, including a loss of KRW 12.3144 billion in 2025.

Operating cash flow also posted net outflows of KRW 8.2 to 11.1 billion each year over the same period, meaning operating cash generation alone has not covered the cost base. Visibility on when the company might reach breakeven remains limited.

Quarterly Earnings Volatility and Order-Dependent Revenue

Quarterly revenue fell for two consecutive quarters, from KRW 1.84935 billion in 2025 Q4 to KRW 1.32486 billion in 2026 Q1 and KRW 1.17562 billion in Q2.

Over the same period the operating loss widened from KRW 3.2519 billion to KRW 4.4572 billion, reflecting both lower revenue and sustained cost pressure simultaneously. The structure in which quarterly results can swing sharply depending on whether a small number of large contracts close also persists.

Non-Operating Earnings Volatility and Funding/Dilution Risk

Total liabilities surged from KRW 4.9145 billion in 2023 to KRW 21.9231 billion in 2024, consistent with the impact of financing instruments such as convertible bonds.

In 2025 Q2, the net loss attributable to owners (KRW 18.2618 billion) far exceeded the operating loss (KRW 3.9575 billion), suggesting a large swing in non-operating items possibly related to convertible-bond valuation.

Given continued cash burn, additional funding may be needed going forward, and the possibility of share dilution from such financing cannot be ruled out.

Risk factors

Profitability and Cash Flow Risk

The company has recorded both an operating loss and negative operating cash flow every year from 2022 through 2025. If the pace of software revenue expansion falls short of expectations, improvement in the cost structure could be delayed. No official timeline for reaching breakeven has been provided.

Funding and Dilution Risk

The sharp rise in total liabilities between 2023 and 2024 indicates reliance on financing instruments such as convertible bonds.

Given the persistent cash-burn structure, further equity issuance or bond issuance cannot be ruled out, and conversion of outstanding bonds could increase share count and dilute existing holders.

Customer Decision-Making and Competitive Risk

In a September 2026 interview, CEO Nam-yong Kim noted that because the comprehensive-contract model is new, decision-making by big pharma executives has been slower than expected.

While Pluto Code's design for compatibility with competitor equipment from Beckman Coulter and Hamilton favors market diffusion, it also leaves open the possibility that these competitors could develop similar software layers of their own.

If revenue becomes concentrated among a small number of large customers or contracts, the impact of any delay or failure of a specific deal on results could be amplified.

What to watch next

By November 16, 2026 (statutory filing deadline for the Q3 report)
Check the 2026 Q3 revenue and operating loss trend to assess whether the operating-loss widening seen in Q2 was a temporary phenomenon or a more structural pattern.
During the fourth quarter of 2026
Confirm through subsequent disclosures and media reports whether the AI-based data analytics collaboration with a large global company that CEO Kim said would be announced around late August to September has actually been formalized.
Within calendar year 2026
Monitor disclosures for whether additional comprehensive license agreements (MLAs) with global pharma or CRO/CDMO companies that the company says are under discussion are signed, and track changes in software's share of total revenue.
At each upcoming quarterly disclosure
Review the status of convertible bond conversions, changes in equity and liabilities, and any additional equity financing to monitor dilution potential and shifts in the balance sheet.

Overall view

Curiox Biosystems has built a track record of transactions with top-tier global biopharma companies on the strength of its niche cell-washing automation technology, and in 2026 its move to shift the business model from hardware sales toward recurring-revenue software licensing has become more concrete.

Revenue rebounded in 2025 after two consecutive years of decline, and tangible progress emerged, including the first comprehensive license agreement for Pluto Code and an order from a global pharmaceutical company in the cell and gene therapy field.

Yet the operating loss and negative operating cash flow continued without interruption every year from 2022 through 2025, and in 2026 Q2 revenue declined while the operating loss widened at the same time, underscoring volatility in the pace of improvement.

Total equity rose despite large losses while total liabilities surged, reflecting the use of instruments such as convertible bonds, so reliance on external funding and the potential for future dilution both warrant attention.

The possibility that big pharma's comprehensive-contract decisions move more slowly than expected, along with a revenue structure concentrated in a small number of large contracts, are also factors to weigh in a balanced way.

Ultimately, how this stock is assessed is likely to hinge on how the expansion of software's revenue share and the timing of any path to breakeven actually materialize.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-10-02 · Data as of 2026-10-01

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.